BrainsWay (BWAY) Competitors

BrainsWay (NASDAQ:BWAY) and Iradimed (NASDAQ:IRMD) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, community ranking, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

Does the MarketBeat Community favor BWAY or IRMD?

Iradimed received 190 more outperform votes than BrainsWay when rated by MarketBeat users. However, 67.31% of users gave BrainsWay an outperform vote while only 65.49% of users gave Iradimed an outperform vote.

Company	Underperform	Outperform
BrainsWay	Outperform Votes 70 67.31%	Underperform Votes 34 32.69%
Iradimed	Outperform Votes 260 65.49%	Underperform Votes 137 34.51%

Which has more volatility & risk, BWAY or IRMD?

BrainsWay has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Comparatively, Iradimed has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500.

Does the media refer more to BWAY or IRMD?

In the previous week, Iradimed had 3 more articles in the media than BrainsWay. MarketBeat recorded 6 mentions for Iradimed and 3 mentions for BrainsWay. BrainsWay's average media sentiment score of 1.03 beat Iradimed's score of 0.91 indicating that BrainsWay is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BrainsWay	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Iradimed	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals and insiders hold more shares of BWAY or IRMD?

30.1% of BrainsWay shares are held by institutional investors. Comparatively, 92.3% of Iradimed shares are held by institutional investors. 19.0% of BrainsWay shares are held by company insiders. Comparatively, 37.1% of Iradimed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Which has preferable earnings & valuation, BWAY or IRMD?

Iradimed has higher revenue and earnings than BrainsWay. Iradimed is trading at a lower price-to-earnings ratio than BrainsWay, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BrainsWay	$41.02M	4.05	-$4.20M	$0.17	51.82
Iradimed	$73.24M	9.19	$19.23M	$1.50	35.29

Is BWAY or IRMD more profitable?

Iradimed has a net margin of 26.26% compared to BrainsWay's net margin of 3.88%. Iradimed's return on equity of 24.12% beat BrainsWay's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BrainsWay	3.88%	3.52%	2.26%
Iradimed	26.26%	24.12%	21.20%

Do analysts rate BWAY or IRMD?

BrainsWay presently has a consensus target price of $13.17, indicating a potential upside of 49.45%. Iradimed has a consensus target price of $72.00, indicating a potential upside of 36.00%. Given BrainsWay's higher possible upside, equities analysts clearly believe BrainsWay is more favorable than Iradimed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BrainsWay	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Iradimed	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Iradimed beats BrainsWay on 11 of the 17 factors compared between the two stocks.